Cancer immunotherapy company CEL-SCI Corporation (NYSE American:CVM) said on Tuesday that the underwriters have announced the full exercise of 90,959 additional shares of common stock in over-allotment option in connection with its underwritten public offering.
The company had issued 606,395m shares of its common stock under its prior underwritten public offering.
Following the full exercise of the underwriters' over-allotment option, the company raised total gross proceeds from the offering of USD6.325m.
Aegis Capital Corp acted as the sole book-running manager for the offering.
CEL-SCI's lead investigational therapy Multikine is currently in a pivotal Phase 3 clinical trial involving head and neck cancer, for which the company has received Orphan Drug Status from the FDA.
Emmaus Life Sciences' Endari label enhancements receive US FDA approval
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma